News. Analysis. Insight.™ - 100 Years of Journalistic Excellence

Covance is a drug development services company that provides a range of early stage and late stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries. Co. also provides laboratory testing services to the chemical, agrochemical and food industries. In addition, Co. maintains offices in more than 20 countries worldwide. Co. operates through two segments: early development services that include preclinical services and clinical pharmacology services; and late-stage development services that include central laboratory, clinical development, periapproval, cardiac safety services and market access services.

Industry	Health
Sector	Biotechnology
# of Employees	8,100
Shares Outstanding	64.0M
Market Cap	3.3B
Enterprise Value	2.2B

52-Week High	$58.95
52-Week Low	$32.31
P/E Ratio	18.29
EPS	$2.81/shr
Dividend	-
Yield	-

Mr. Joseph L. Herring

Chief Executive Officer; Chairman

Mr. William E. Klitgaard

Chief Financial Officer; Senior Vice President; Treasurer

Mr. Wendel Barr

Chief Operating Officer; Executive Vice President

Ms. Michele A. Kennedy

Controller; Vice President; Chief Accounting Officer

Mr. James W. Lovett

Secretary; Senior Vice President; General Counsel

Mr. Donald Kraft

Senior Vice President

Mr. Richard Cimino

Senior Vice President; Division Officer

Ms. Deborah L. Tanner

Senior Vice President; Division Officer

Mr. Anthony Cork

Senior Vice President; Region Officer

Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Investing News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs